Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Jun 16, 2023 7:11pm
293 Views
Post# 35501184

RE:A patent update

RE:A patent update
Pertinent comments from the PDF file (Sorry copy  & paste is/was not available for the PDF file)
 
Reasons for Allowance:
 
The following is an examiner's statement of reasons for allowance:
 
Claims 1-3 and 5-21 of the instant application claim a method for treating cancer comprising administering at least one cannabinoid receptor agonist, administering a photodynamic compound and administering radiation to the subject in whom the at least one cannabinoid receptor agonist and the photodynamic compound are present so as to activate the photodynamic compound to generate at least one of radicals and reactive oxygen species to destroy the cancer cells to treat the cancer, wherein the photodynamic compound is further combined with a metal binding glycoprotein such as transferrin.
 
The Application demonstrates that the addition of a cannabinoid receptor agonist to photodynamic therapy (radiation and a photodynamic compound) produces synergy as shown in the declaration under 37 CFR 1.132 filed on August 26, 2021.
 
Since the "prior art" does not specifically teach the combination of a cannabinoid receptor agonist, a photodynamic compound and moreover since Applicant has discovered that the combination produces synergy in the treatment of cancer 
cells which could not have been predicted in view of the cited prior art, the claims of the instant application are novel, and non-obvious in view of the closest related prior art.
<< Previous
Bullboard Posts
Next >>